R&D and Pipeline


TT-173 is a recombinant human Tissue Factor-based topical hemostat for use in surgical bleeding. Developed as a lyophilized, it is highly stable even at room temperature. After a successful Phase I clinical trial in dental extraction, and a Phase II clinical trial in skin grafting a Phase II/III study in Total Knee Arthroplasty is ongoing.

In addition, new medical devices based on TT-173 are under development in preclinical phase.

Anticoagulant program

New anticoagulant products through unexplored target already validated in vivo model. Under development to start Pre-Clinical stages soon.

Antifibrinolytic program

New highly antifibrinolytic NCEs, with much higher potencies than those commercially available on the market.